CA2506236C - Compositions and uses of dalbavancin for treatment of bacterial infections - Google Patents
Compositions and uses of dalbavancin for treatment of bacterial infections Download PDFInfo
- Publication number
- CA2506236C CA2506236C CA2506236A CA2506236A CA2506236C CA 2506236 C CA2506236 C CA 2506236C CA 2506236 A CA2506236 A CA 2506236A CA 2506236 A CA2506236 A CA 2506236A CA 2506236 C CA2506236 C CA 2506236C
- Authority
- CA
- Canada
- Prior art keywords
- dose
- dalbavancin
- amount
- subsequent
- initial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960002488 dalbavancin Drugs 0.000 title claims abstract description 686
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 title claims abstract description 686
- 108700009376 dalbavancin Proteins 0.000 title claims abstract description 685
- 238000011282 treatment Methods 0.000 title claims abstract description 142
- 208000035143 Bacterial infection Diseases 0.000 title claims abstract description 128
- 208000022362 bacterial infectious disease Diseases 0.000 title claims abstract description 82
- 239000000203 mixture Substances 0.000 title abstract description 92
- 239000003814 drug Substances 0.000 claims description 111
- 239000008194 pharmaceutical composition Substances 0.000 claims description 58
- 239000003937 drug carrier Substances 0.000 claims description 45
- 206010062255 Soft tissue infection Diseases 0.000 claims description 40
- 206010040872 skin infection Diseases 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 241000191967 Staphylococcus aureus Species 0.000 claims description 14
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 10
- 241000192125 Firmicutes Species 0.000 claims description 9
- 238000000034 method Methods 0.000 abstract description 60
- 230000003442 weekly effect Effects 0.000 abstract description 17
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000002035 prolonged effect Effects 0.000 abstract description 6
- 210000004872 soft tissue Anatomy 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 109
- 230000027455 binding Effects 0.000 description 75
- 229910001868 water Inorganic materials 0.000 description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- BEVDFPMXVNOQBI-AXNWEOKVSA-N (19R,22R,34S,37R,40R,52S)-64-[(2S,3R,4R,5S,6S)-3-amino-6-carboxy-4,5-dihydroxyoxan-2-yl]oxy-5,32-dichloro-2,26,31,49-tetrahydroxy-22-(methylamino)-21,35,38,54,56,59-hexaoxo-47-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14(63),15,17(62),23(61),24,26,29(60),30,32,41,43,45(57),46(51),47,49,65-henicosaene-52-carboxylic acid Chemical compound CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)C(O)C7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3cccc(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(O)=O)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3N)C(O)=O)cc4)NC1=O)c2 BEVDFPMXVNOQBI-AXNWEOKVSA-N 0.000 description 60
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 60
- 108700027524 A 40926 Proteins 0.000 description 58
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 51
- 229940079593 drug Drugs 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 43
- 239000000178 monomer Substances 0.000 description 38
- 230000000694 effects Effects 0.000 description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 210000002381 plasma Anatomy 0.000 description 36
- 208000015181 infectious disease Diseases 0.000 description 34
- 230000003115 biocidal effect Effects 0.000 description 33
- 238000001990 intravenous administration Methods 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 230000036470 plasma concentration Effects 0.000 description 25
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 24
- 108010059993 Vancomycin Proteins 0.000 description 23
- 238000003756 stirring Methods 0.000 description 23
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 23
- 229960003165 vancomycin Drugs 0.000 description 22
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 22
- 108010053950 Teicoplanin Proteins 0.000 description 21
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 21
- 229960001608 teicoplanin Drugs 0.000 description 21
- 230000000844 anti-bacterial effect Effects 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 230000003993 interaction Effects 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 230000002411 adverse Effects 0.000 description 18
- 239000011347 resin Substances 0.000 description 18
- 229920005989 resin Polymers 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- 239000003242 anti bacterial agent Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 244000052769 pathogen Species 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 15
- 238000000111 isothermal titration calorimetry Methods 0.000 description 15
- 230000002906 microbiologic effect Effects 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 108091006905 Human Serum Albumin Proteins 0.000 description 13
- 102000008100 Human Serum Albumin Human genes 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 230000000087 stabilizing effect Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 239000000539 dimer Substances 0.000 description 11
- 238000009826 distribution Methods 0.000 description 11
- 238000001802 infusion Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000001819 mass spectrum Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000008029 eradication Effects 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000003381 stabilizer Substances 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- -1 multimers (i.e. Substances 0.000 description 8
- 230000036963 noncompetitive effect Effects 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 241000194017 Streptococcus Species 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 239000008121 dextrose Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 244000000059 gram-positive pathogen Species 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 238000001728 nano-filtration Methods 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 206010011409 Cross infection Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000004952 Polyamide Substances 0.000 description 6
- 206010040047 Sepsis Diseases 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000013011 aqueous formulation Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 208000037815 bloodstream infection Diseases 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000012466 permeate Substances 0.000 description 6
- 229920002647 polyamide Polymers 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 108010015899 Glycopeptides Proteins 0.000 description 5
- 102000002068 Glycopeptides Human genes 0.000 description 5
- 238000010268 HPLC based assay Methods 0.000 description 5
- 241000295644 Staphylococcaceae Species 0.000 description 5
- 238000007112 amidation reaction Methods 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 238000012421 spiking Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000009435 amidation Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000005567 liquid scintillation counting Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 239000011698 potassium fluoride Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 235000011149 sulphuric acid Nutrition 0.000 description 4
- 238000011477 surgical intervention Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000012465 retentate Substances 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- DEBZEVJNWCNATM-MZWXYZOWSA-N 2,2,4,4,6,6-hexakis(deuteriomethyl)-1,3,5-triaza-2lambda5,4lambda5,6lambda5-triphosphacyclohexa-1,3,5-triene Chemical compound [2H]CP1(C[2H])=NP(C[2H])(C[2H])=NP(C[2H])(C[2H])=N1 DEBZEVJNWCNATM-MZWXYZOWSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108700005306 BI 397 Proteins 0.000 description 2
- 101000693927 Canis lupus familiaris Albumin Proteins 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 206010029803 Nosocomial infection Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101000930457 Rattus norvegicus Albumin Proteins 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010042566 Superinfection Diseases 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000011203 antimicrobial therapy Methods 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- KGPGQDLTDHGEGT-SZUNQUCBSA-N dalbavancin Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-SZUNQUCBSA-N 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000005040 ion trap Methods 0.000 description 2
- 150000002542 isoureas Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920006122 polyamide resin Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- LVRCEUVOXCJYSV-UHFFFAOYSA-N CN(C)S(=O)=O Chemical compound CN(C)S(=O)=O LVRCEUVOXCJYSV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 206010051723 Fluctuance Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010060708 Induration Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241001647788 Nonomuraea Species 0.000 description 1
- GEHJHDIWXQAIOS-UHFFFAOYSA-N O[S+]1C2=CC=CC=C2N=C1.O Chemical compound O[S+]1C2=CC=CC=C2N=C1.O GEHJHDIWXQAIOS-UHFFFAOYSA-N 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009146 cooperative binding Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000002334 isothermal calorimetry Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000379 polypropylene carbonate Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000009258 post-therapy Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000009119 stepdown therapy Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960001572 vancomycin hydrochloride Drugs 0.000 description 1
- LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42765402P | 2002-11-18 | 2002-11-18 | |
| US60/427,654 | 2002-11-18 | ||
| US48569403P | 2003-07-08 | 2003-07-08 | |
| US60/485,694 | 2003-07-08 | ||
| US49504803P | 2003-08-13 | 2003-08-13 | |
| US60/495,048 | 2003-08-13 | ||
| US49648303P | 2003-08-19 | 2003-08-19 | |
| US60/496,483 | 2003-08-19 | ||
| PCT/US2003/036127 WO2004045636A1 (en) | 2002-11-18 | 2003-11-14 | Methods of administering dalbavancin for treatment of bacterial infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2506236A1 CA2506236A1 (en) | 2004-06-03 |
| CA2506236C true CA2506236C (en) | 2018-07-17 |
Family
ID=32330046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2506236A Expired - Lifetime CA2506236C (en) | 2002-11-18 | 2003-11-14 | Compositions and uses of dalbavancin for treatment of bacterial infections |
Country Status (14)
| Country | Link |
|---|---|
| US (12) | US20050130909A1 (https=) |
| EP (1) | EP1565201B1 (https=) |
| JP (3) | JP5519090B2 (https=) |
| KR (2) | KR101173310B1 (https=) |
| AU (3) | AU2003299561A1 (https=) |
| CA (1) | CA2506236C (https=) |
| DK (1) | DK1565201T3 (https=) |
| ES (1) | ES2712656T3 (https=) |
| HU (1) | HUE041133T2 (https=) |
| IL (3) | IL168327A (https=) |
| MX (1) | MXPA05005338A (https=) |
| NO (1) | NO20052362L (https=) |
| PT (1) | PT1565201T (https=) |
| WO (3) | WO2004045637A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119061B2 (en) * | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
| AU2003299561A1 (en) * | 2002-11-18 | 2004-06-15 | Vicuron Pharmaceuticals Inc. | Compositions and methods for treating bacterial infections with protein-dalbavancin complexes |
| US20060074014A1 (en) * | 2002-11-18 | 2006-04-06 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20090062182A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched dalbavancin |
| US8389583B2 (en) * | 2008-05-23 | 2013-03-05 | Zurex Pharma, Inc. | Antimicrobial compositions and methods of use |
| US20110132607A1 (en) * | 2009-12-07 | 2011-06-09 | Schlumberger Technology Corporation | Apparatus and Technique to Communicate With a Tubing-Conveyed Perforating Gun |
| CA2904387C (en) | 2013-03-15 | 2021-12-07 | Melinta Therapeutics, Inc. | Methods of treating infections in overweight and obese patients using antibiotics |
| JP6540705B2 (ja) | 2013-12-19 | 2019-07-10 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 生物学的液体処理システムのための遠隔操作弁 |
| EP4509178A3 (en) | 2014-07-17 | 2025-06-25 | Melinta Therapeutics, LLC | High purity oritavancin and method of producing same |
| HUE053347T2 (hu) | 2014-11-06 | 2021-06-28 | Xellia Pharmaceuticals Aps | Glikopeptid-készítmények |
| WO2016140981A1 (en) * | 2015-03-02 | 2016-09-09 | Colonaryconcepts Llc | Compounds and methods for peg metabolite and peg breakdown product assays |
| JP6983660B2 (ja) | 2015-05-08 | 2021-12-17 | スペクトラル プラットフォームス インコーポレイテッド | アルブミンに基づく非共有結合性複合体およびその使用方法 |
| WO2017179003A1 (en) | 2016-04-15 | 2017-10-19 | Lupin Limited | Topical compositions for ophthalmic and otic use |
| WO2018175346A1 (en) | 2017-03-20 | 2018-09-27 | Spectral Platforms, Inc. | Spectroscopic methods to detect and characterize microorganisms |
| US20220023399A1 (en) * | 2017-07-10 | 2022-01-27 | Contrafect Corporation | Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof |
| CN110183519B (zh) * | 2019-05-06 | 2023-04-11 | 大邦(湖南)生物制药有限公司 | 一种达巴万星关键中间体a40926的分离纯化方法 |
| CN112480214B (zh) * | 2020-12-14 | 2023-03-28 | 成都雅途生物技术有限公司 | 一种达巴万星关键中间体a40926的制备方法 |
| EP4014965A1 (en) * | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| CA3204571A1 (en) | 2021-01-11 | 2022-07-14 | Vidar Bjornstad | Synthesis process |
| CN115215926A (zh) * | 2022-08-12 | 2022-10-21 | 丽珠集团福州福兴医药有限公司 | 达巴万星母核及其纯化方法、达巴万星及其合成方法 |
| AU2023359653A1 (en) * | 2022-10-12 | 2025-05-29 | Hikma Pharmaceuticals Usa Inc. | Liquid dalbavancin composition |
| EP4601615A1 (en) | 2022-10-12 | 2025-08-20 | Hikma Pharmaceuticals USA Inc. | Liquid dalbavancin composition |
| EP4431083A1 (en) | 2023-03-16 | 2024-09-18 | Adalvo Limited | Formulation of dalbavancin |
| EP4431084A1 (en) | 2023-03-16 | 2024-09-18 | Adalvo Limited | Formulation of dalbavancin |
| WO2025158262A1 (en) | 2024-01-23 | 2025-07-31 | Lupin Limited | Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation |
| GB202405996D0 (en) * | 2024-04-29 | 2024-06-12 | Arecor Ltd | Novel compositions |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US541616A (en) * | 1895-06-25 | Elevator attachment | ||
| US573679A (en) * | 1896-12-22 | Apparatus for mowing hay | ||
| GB1496386A (en) * | 1975-03-05 | 1977-12-30 | Lepetit Spa | Antibiotics |
| US4195079A (en) * | 1979-01-31 | 1980-03-25 | Pfizer Inc. | New polycyclic ether antibiotic |
| CA1183789A (en) | 1981-08-04 | 1985-03-12 | Kiyoshi Isono | Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient |
| US4578271A (en) | 1982-05-24 | 1986-03-25 | Fujisawa Pharmaceutical Co., Ltd. | Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions |
| FI73697C (fi) * | 1982-06-08 | 1987-11-09 | Lepetit Spa | Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2. |
| FR2548021B1 (fr) | 1983-06-29 | 1986-02-28 | Dick P R | Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels |
| GB8415092D0 (en) * | 1984-06-13 | 1984-07-18 | Lepetit Spa | Ester derivatives |
| GB8425685D0 (en) | 1984-10-11 | 1984-11-14 | Lepetit Spa | Antibiotic a 40926 complex |
| GB8428619D0 (en) * | 1984-11-13 | 1984-12-19 | Lepetit Spa | Derivatives of antibiotic l 17046 |
| US4914187A (en) * | 1984-11-13 | 1990-04-03 | Gruppo Lepetit S.P.A | Ester derivatives of antibiotic L 17046 |
| GB8512795D0 (en) | 1985-05-21 | 1985-06-26 | Lepetit Spa | Increasing ratio of components of teicoplanin a2 complex |
| GB8531846D0 (en) * | 1985-12-30 | 1986-02-05 | Lepetit Spa | Antibiotic a 40926 mannosyl aglycon |
| GB8608809D0 (en) * | 1986-04-11 | 1986-05-14 | Lepetit Spa | Antibiotic |
| GB8621912D0 (en) | 1986-09-11 | 1986-10-15 | Lepetit Spa | Increasing ratio of components of anti-biotic complex |
| GB8621911D0 (en) * | 1986-09-11 | 1986-10-15 | Lepetit Spa | Increasing ratio of components of anti-biotic complex |
| GR871488B (en) | 1986-10-10 | 1987-11-12 | Lepetit Spa | New antibiotics |
| GB8715735D0 (en) * | 1987-07-03 | 1987-08-12 | Lepetit Spa | De-mannosyl teicoplanin derivatives |
| US4882313A (en) * | 1987-07-31 | 1989-11-21 | Smithkline Beckman Corporation | Carboxamide derivatives of glycopeptides |
| GB8726859D0 (en) | 1987-11-17 | 1987-12-23 | Lepetit Spa | 22-dechlorotei-coplanins |
| US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
| FR2628269B1 (fr) * | 1988-03-04 | 1990-07-27 | Sgs Thomson Microelectronics | Dispositif de demarrage progressif d'une alimentation a decoupage |
| ATE134646T1 (de) | 1988-12-27 | 1996-03-15 | Lepetit Spa | C63-amidderivate von 34-de(acetylglucosaminyl)-34-deoxy-teicoplanine |
| IE64155B1 (en) | 1989-03-29 | 1995-07-12 | Lepetit Spa | New substituted alkylamide derivatives of teicoplanin |
| JPH03193735A (ja) | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | グリコペプチド系抗生物質の安定化組成物 |
| US5030619A (en) * | 1990-04-16 | 1991-07-09 | Miles Inc. | Synergistic fungicidal composition |
| US5606036A (en) * | 1991-03-27 | 1997-02-25 | Gruppo Lepetit Spa | Antibiotic A 40926 ester derivatives |
| JP2783722B2 (ja) * | 1991-07-12 | 1998-08-06 | 麒麟麦酒株式会社 | スピカマイシン誘導体およびそれを含む抗腫瘍剤 |
| US5750509A (en) * | 1991-07-29 | 1998-05-12 | Gruppo Lepetit S.P.A. | Amide derivatives of antibiotic A 40926 |
| KR100242682B1 (ko) | 1991-07-29 | 2000-02-01 | 클라우디오 쿼르타 | 항생물질 a 40926의 아미드 유도체 |
| US6384013B1 (en) * | 1992-03-19 | 2002-05-07 | Eli Lilly And Company | Cyclic peptide antifungal agents and process for preparation thereof |
| US5882900A (en) * | 1992-09-10 | 1999-03-16 | Gruppo Lepetit S.P.A. | Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium |
| CA2112776C (en) * | 1993-01-21 | 2002-11-12 | Masakazu Tsuchiya | Process for inhibiting activity of endotoxin |
| ATE235549T1 (de) * | 1993-04-30 | 2003-04-15 | Biognostik Ges | Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2 |
| SI0801655T1 (en) * | 1995-02-07 | 1998-08-31 | Biosearch Italia S.P.A. | Basic proline-amide derivatives of ge 2270 and ge 2270-like antibiotics |
| SI9500039B (sl) * | 1995-02-07 | 2002-02-28 | Lek, | Nov kombiniran postopek čiščenja Vankomicin hidroklorida |
| JP3518606B2 (ja) * | 1995-02-07 | 2004-04-12 | バイオサーチ・イタリア・ソチエタ・ペル・アチオニ | Ｇｅ２２７０及びｇｅ２２７０−様抗生物質の塩基性オキサゾリン−アミド誘導体 |
| US5789308A (en) * | 1995-06-06 | 1998-08-04 | Advanced Micro Devices, Inc. | Manufacturing method for wafer slice starting material to optimize extrinsic gettering during semiconductor fabrication |
| CA2180206A1 (en) * | 1995-06-30 | 1996-12-31 | Motoya Ohshika | Freeze-dried preparation for pharmaceutical use |
| DE69633234T2 (de) * | 1995-07-05 | 2005-09-15 | Aventis Bulk S.P.A. | Reinigung von dalbeheptide-antibiotika mittels isoelektrofokussierung |
| DE19600590A1 (de) * | 1996-01-10 | 1997-07-24 | Tzn Forschung & Entwicklung | Schutzvorrichtung für optische Systeme zur Vermeidung von Schäden bei Bestrahlung dieser Systeme mit Laserlicht |
| JP2000505438A (ja) * | 1996-02-14 | 2000-05-09 | バイオサーチ・イタリア・ソチエタ・ペル・アチオニ | 抗生物質ＧＥ２２７０因子Ｃ▲下２ａ▼、Ｄ▲下２▼およびＥの誘導体 |
| AU2441697A (en) | 1996-04-12 | 1997-11-07 | Eli Lilly And Company | Covalently-linked glycopeptide dimers |
| KR20000010589A (ko) * | 1996-04-23 | 2000-02-15 | 클라우디오 쿼르타 | 항생제a40926의아미드유도체의개선된화학적제조방법 |
| US5935238A (en) * | 1997-06-19 | 1999-08-10 | Sun Microsystems, Inc. | Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles |
| JP4204655B2 (ja) * | 1997-08-08 | 2009-01-07 | 株式会社ルネサステクノロジ | パルス出力機能付マイクロコンピュータ |
| CA2255140A1 (en) | 1997-12-23 | 1999-06-23 | Eli Lilly And Company | Echinocandin binding domain of 1,3-.beta.-glucan synthase |
| US6541616B1 (en) * | 1998-10-01 | 2003-04-01 | Antex Biologics Inc. | Moraxella catarrhalis protein, gene sequence and uses thereof |
| US6417180B1 (en) | 1998-10-07 | 2002-07-09 | University Of Massachusetts | Zinc finger-reactive antimicrobial compounds |
| DE69908819T2 (de) * | 1998-12-23 | 2004-05-06 | Theravance, Inc., South San Francisco | Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten |
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| US6770621B2 (en) | 2000-05-02 | 2004-08-03 | Theravance, Inc. | Polyacid glycopeptide derivatives |
| WO2003070756A2 (de) | 2002-02-18 | 2003-08-28 | Combinature Biopharm Ag | Neue glycopeptid-antibiotika und verfahren zu deren synthetisierung |
| US7119061B2 (en) | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
| AU2003299561A1 (en) | 2002-11-18 | 2004-06-15 | Vicuron Pharmaceuticals Inc. | Compositions and methods for treating bacterial infections with protein-dalbavancin complexes |
-
2003
- 2003-11-14 AU AU2003299561A patent/AU2003299561A1/en not_active Abandoned
- 2003-11-14 ES ES03789744T patent/ES2712656T3/es not_active Expired - Lifetime
- 2003-11-14 WO PCT/US2003/036779 patent/WO2004045637A1/en not_active Ceased
- 2003-11-14 DK DK03789744.4T patent/DK1565201T3/en active
- 2003-11-14 EP EP03789744.4A patent/EP1565201B1/en not_active Expired - Lifetime
- 2003-11-14 WO PCT/US2003/036399 patent/WO2004046196A2/en not_active Ceased
- 2003-11-14 HU HUE03789744A patent/HUE041133T2/hu unknown
- 2003-11-14 KR KR1020057008951A patent/KR101173310B1/ko not_active Expired - Lifetime
- 2003-11-14 US US10/714,166 patent/US20050130909A1/en not_active Abandoned
- 2003-11-14 WO PCT/US2003/036127 patent/WO2004045636A1/en not_active Ceased
- 2003-11-14 US US10/714,261 patent/US6900175B2/en active Active
- 2003-11-14 US US10/493,558 patent/US20050090433A1/en not_active Abandoned
- 2003-11-14 CA CA2506236A patent/CA2506236C/en not_active Expired - Lifetime
- 2003-11-14 AU AU2003294262A patent/AU2003294262B2/en not_active Expired
- 2003-11-14 US US10/713,924 patent/US20050004011A1/en not_active Abandoned
- 2003-11-14 AU AU2003298662A patent/AU2003298662A1/en not_active Abandoned
- 2003-11-14 MX MXPA05005338A patent/MXPA05005338A/es active IP Right Grant
- 2003-11-14 JP JP2004570384A patent/JP5519090B2/ja not_active Expired - Lifetime
- 2003-11-14 KR KR1020127012832A patent/KR20120056310A/ko not_active Ceased
- 2003-11-14 PT PT03789744T patent/PT1565201T/pt unknown
-
2004
- 2004-04-16 US US10/828,483 patent/US20040198715A1/en not_active Abandoned
- 2004-04-16 US US10/828,439 patent/US7115564B2/en not_active Expired - Lifetime
- 2004-04-16 US US10/828,379 patent/US20040220122A1/en not_active Abandoned
- 2004-04-20 US US10/829,068 patent/US20040224908A1/en not_active Abandoned
- 2004-09-15 US US10/942,604 patent/US20050130914A1/en not_active Abandoned
- 2004-09-15 US US10/942,197 patent/US20050032721A1/en not_active Abandoned
-
2005
- 2005-05-02 IL IL168327A patent/IL168327A/en active IP Right Grant
- 2005-05-12 NO NO20052362A patent/NO20052362L/no not_active Application Discontinuation
-
2009
- 2009-05-28 US US12/473,390 patent/US20090298748A1/en not_active Abandoned
- 2009-05-29 US US12/474,438 patent/US20090305953A1/en not_active Abandoned
-
2011
- 2011-04-05 JP JP2011083790A patent/JP2011157381A/ja active Pending
-
2013
- 2013-04-16 JP JP2013085785A patent/JP2013155188A/ja active Pending
-
2014
- 2014-02-06 IL IL230875A patent/IL230875A0/en unknown
-
2015
- 2015-07-13 IL IL239913A patent/IL239913B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2506236C (en) | Compositions and uses of dalbavancin for treatment of bacterial infections | |
| AU2011200423B2 (en) | Dalbavancin compositions for treatment of bacterial infections | |
| US8143212B2 (en) | Dalbavancin compositions for treatment of bacterial infections | |
| ZA200503695B (en) | Methods of administering dalbavancin for treatment of bacterial infections | |
| HK1114014B (en) | Pharmaceutical composition comprising dalbavancin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20231114 |